^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

CNS Tumor

Related cancers:
3d
Integrated high-resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34-mutant reveals universal TP53 abnormalities. (PubMed, Brain Pathol)
Collectively, a TP53 abnormality at copy number (12/26, all cnLOH), sequence (55/60) and protein expression (46/48) level was detected in all 60 cases. In conclusion, integrated high-resolution copy number and histomolecular analysis expanded the spectrum of genetic changes associated with DHG-H3 G34, including the presence of universal TP53 abnormalities with frequent cnLOH-a copy number abnormality that has been largely unrecognized-for this new 2021 World Health Organization central nervous system tumor type.
Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PMS2 (PMS1 protein homolog 2) • ATRX (ATRX Chromatin Remodeler) • H3-3A (H3.3 Histone A) • OLIG2 (Oligodendrocyte Transcription Factor 2)
|
TP53 mutation
3d
PTPN11-Related Noonan Syndrome Predisposes to Multifocal Low-Grade CNS Tumors Harboring FGFR1 Variants. (PubMed, Res Sq)
PTPN11 -related NS predisposes to multifocal pure and mixed LGGs confirmed by radiological, histological, and molecular characteristics. Targeting FGFR1-related pathways may provide new treatment approaches for patients with NS and LGGs.
Clinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
3d
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) (clinicaltrials.gov)
P2, N=54, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting | Trial completion date: Jan 2029 --> Feb 2030
Enrollment open • Trial completion date
4d
B7-H3.CD28Z.CART in CNS Neoplasms (clinicaltrials.gov)
P1, N=70, Not yet recruiting, Robbie Majzner
New P1 trial
|
CD276 (CD276 Molecule)
|
cyclophosphamide • fludarabine IV
4d
Gamma-glutamyl transferase as a redox-gatekeeper biomarker for pancreatic cystic neoplasms: A concise roadmap from epidemiology to bedside. (PubMed, World J Gastroenterol)
We propose: (1) Refining age-specific GGT thresholds via repeated measurements and restricted cubic splines; (2) Integrating GGT with carbohydrate antigen 19-9, carcinoembryonic antigen, and KRAS/GNAS circulating tumor DNA in machine-learning radiomic models for personalized 5-year malignancy risks per Fukuoka guidelines; and (3) Validating cost-effectiveness in multi-ethnic populations before screening. This repositions GGT as a globally available redox biosignature for PCN early detection, potentially reducing pancreatic cancer burden.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • IL6 (Interleukin 6) • CEACAM5 (CEA Cell Adhesion Molecule 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • GNAS (GNAS Complex Locus) • IL6ST (Interleukin 6 Signal Transducer)
4d
Presentation and Outcomes of CNS Tumors Associated With Phakomatoses Syndromes From a Specialized Neuro-Oncology Practice in India. (PubMed, Cancer Med)
Phakomatoses-associated CNS tumors show promising outcomes with multimodality management. Further research into targeted multimodality treatment is warranted.
Retrospective data • Journal
|
NF1 (Neurofibromin 1)
4d
Two pediatric supratentorial ependymal tumors with novel PLAG1 fusions. (PubMed, Acta Neuropathol Commun)
They also represent the first PLAG1 fusions identified in pediatric supratentorial ependymal tumors. These cases highlight the value of integrating histology, methylation profiling, and fusion detection, and suggest a new candidate supratentorial ependymal subtype with PLAG1 fusions, pending validation in larger series.
Journal
|
ATRX (ATRX Chromatin Remodeler) • CD34 (CD34 molecule) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • L1CAM (L1 cell adhesion molecule) • PLAG1 (PLAG1 Zinc Finger) • TXNIP (Thioredoxin Interacting Protein) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2) • PLAGL2 (PLAG1 Like Zinc Finger 2)
5d
Epstein-Barr virus (EBV)-associated smooth muscle tumor of the central nervous system in an HIV patient: diagnostic and therapeutic challenges. (PubMed, BMC Infect Dis)
Epstein-Barr virus (EBV)-associated smooth muscle rare tumors (EBV-SMTs) in HIV patients with low CD4 counts require clinical suspicion and Epstein-Barr virus (EBV) involvement in brain tumor diagnosis. Early HIV detection, CD4 monitoring, and antiretroviral therapy (ART) management can decrease the risk of these malignancies.
Journal
|
CD4 (CD4 Molecule)
5d
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma. (PubMed, Neuro Oncol)
B7-H3 CAR T cells combined with ONC206 is a feasible and efficacious multi-agent approach against multiple DIPG models.
Preclinical • Journal
|
CD276 (CD276 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • IFNL1 (Interferon Lambda 1)
|
JZP3507
5d
Potent antitumor activity through dual targeting of PD-L1 and TGF-β pathways in the glioma tumor microenvironment. (PubMed, J Immunother Cancer)
Our findings provide strong support for the combined targeting of TGF-β and PD-L1 as a promising immunotherapeutic strategy to overcome immunosuppressive barriers in glioblastoma and induce potent antitumor responses.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression
|
bintrafusp alfa (M7824)
5d
Metastatic extra-axial medulloblastoma involving the trigeminal nerve: a rare prognostic entity with a comprehensive literature review. (PubMed, Front Oncol)
Around 5-6% of MBs are associated with inherited cancer predisposition syndromes, with common genetic variants including PTCH1, SUFU, TP53, and SMO. This report describes the first pediatric patient harboring a CHEK2 germline variant of uncertain significance and developing a EA- MB localized at the trigeminal nerve and subsequent CNS and EN metastases.
Review • Journal
|
TP53 (Tumor protein P53) • PTCH1 (Patched 1) • CHEK2 (Checkpoint kinase 2)
5d
NEMO: Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors (clinicaltrials.gov)
P=N/A, N=600, Not yet recruiting, Tata Memorial Centre | Initiation date: Dec 2025 --> Mar 2026
Trial initiation date